MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-12-2026
Check-Cap Ltd. Market Cap 2011-2026 | CHEK
As of May 26, 2026 Check-Cap Ltd. has a market cap of $ 9.42 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Check-Cap Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 4.33 M | 13.3 M | 15.6 M | 2.55 M | 2.11 M | 11.8 M | 7.79 B | 12.6 B | 33.7 M | 24.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 B | 2.11 M | 2.05 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B |  USA |
 |
Fulgent Genetics
FLGT
|
527 M | $ 17.54 | 2.51 % | $ 540 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 119.6 | 0.55 % | $ 15 B | USA |
 |
Agilent Technologies
A
|
42 B | $ 115.32 | 0.31 % | $ 35.1 B | USA |
 |
Celcuity
CELC
|
5.37 B | $ 135.32 | -2.11 % | $ 6.33 B | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
16.4 B | $ 145.78 | 0.95 % | $ 23.2 B | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 7.04 | 38.83 % | $ 9.36 M | USA |
 |
Castle Biosciences
CSTL
|
472 M | $ 19.68 | -2.33 % | $ 570 M | USA |
 |
Aspira Women's Health
AWH
|
3.03 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
4.03 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
993 M | $ 21.8 | 0.79 % | $ 1.16 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 1.8 | -1.1 % | $ 7.96 M | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 100.3 | -2.62 % | $ 6.77 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 114.32 | -2.11 % | $ 9.43 B |  Irlanda |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 100.85 | -0.2 % | $ 22.7 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
304 M | - | - | $ 399 M |  China |
 |
NeoGenomics
NEO
|
1.48 B | $ 9.22 | -0.11 % | $ 1.18 B | USA |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
133 M | - | - | $ 7.1 B |  Australia |
 |
National Research Corporation
NRC
|
315 M | $ 18.99 | -0.47 % | $ 425 M | USA |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Natera
NTRA
|
5.31 B | $ 203.42 | 0.11 % | $ 20 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 156.53 | -2.35 % | $ 7.76 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 426.76 | -1.4 % | $ 12.3 B | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 3.78 | -1.18 % | $ 350 M | USA |
 |
Personalis
PSNL
|
431 M | $ 9.02 | 6.49 % | $ 805 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.3 B | $ 26.87 | -0.3 % | $ 25.5 B |  Niderland |
 |
Senseonics Holdings
SENS
|
351 M | $ 6.47 | 1.97 % | $ 270 M | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.08 B | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.44 | -1.81 % | $ 5.6 M | USA |
 |
Twist Bioscience Corporation
TWST
|
1.56 B | $ 64.81 | 7.0 % | $ 3.88 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 259.66 | -0.1 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 449.1 | 0.18 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
194 M | $ 0.64 | 6.3 % | $ 230 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K |  Israel |
 |
Waters Corporation
WAT
|
19.7 B | $ 341.01 | -0.4 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 8.97 | 0.73 % | $ 1.95 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 193.85 | -0.7 % | $ 21.5 B | USA |